David N Parente1, Wouter P Kluijfhout1, Pim J Bongers1, Raoul Verzijl1, Karen M Devon1,2, Lorne E Rotstein1, David P Goldstein3, Sylvia L Asa4, Ozgur Mete4, Jesse D Pasternak5. 1. Division of General Surgery, University Health Network, Toronto General Hospital, 200 Elizabeth St. Room 10EN-214, Toronto, ON, M5G 2C4, Canada. 2. Department of Surgery, Womens College Hospital, Toronto, ON, Canada. 3. Otolaryngology Head and Neck Surgery, University Health Network, 610 University Ave. Room 3-952, Toronto, ON, M5G 2M9, Canada. 4. Department of Pathology, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada. 5. Division of General Surgery, University Health Network, Toronto General Hospital, 200 Elizabeth St. Room 10EN-214, Toronto, ON, M5G 2C4, Canada. jesse.pasternak@uhn.ca.
Abstract
BACKGROUND: Renaming encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) to noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was recently suggested to prevent the overtreatment, cost and stigma associated with this low-risk entity. The purpose of this study is to document the incidence and further assess the clinical outcomes of reclassifying EFVPTC to NIFTP. METHODS: We searched synoptic pathologic reports from a high-volume academic endocrine surgery hospital from 2004 to 2013. The standard of surgical pathology practice was based on complete submission of malignant thyroid nodules along with the nontumorous thyroid parenchyma. Rigid morphological criteria were used for the diagnosis of noninvasive EFVPTC, currently known as NIFTP. A retrospective chart review was conducted looking for evidence of malignant behavior. RESULTS: One hundred and two patients met the strict inclusion criteria of NIFTP. The incidence of NIFTP in our cohort was 2.1% of papillary thyroid cancer cases during the studied time period. Mean follow-up was 5.7 years (range 0-11). Five patients were identified with nodal metastasis and one patient with distant metastasis. Overall, six patients showed evidence of malignant behavior representing 6% of patients with NIFTP. CONCLUSION: Our study demonstrates that the incidence of NIFTP is significantly lower than previously thought. Furthermore, evidence of malignant behavior was seen in a significant number of NIFTP patients. Although the authors fully support the de-escalation of aggressive treatment for low-risk thyroid cancers, NIFTP behaves as a low-risk thyroid cancer rather than a benign entity and ongoing surveillance is warranted.
BACKGROUND: Renaming encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) to noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was recently suggested to prevent the overtreatment, cost and stigma associated with this low-risk entity. The purpose of this study is to document the incidence and further assess the clinical outcomes of reclassifying EFVPTC to NIFTP. METHODS: We searched synoptic pathologic reports from a high-volume academic endocrine surgery hospital from 2004 to 2013. The standard of surgical pathology practice was based on complete submission of malignant thyroid nodules along with the nontumorous thyroid parenchyma. Rigid morphological criteria were used for the diagnosis of noninvasive EFVPTC, currently known as NIFTP. A retrospective chart review was conducted looking for evidence of malignant behavior. RESULTS: One hundred and two patients met the strict inclusion criteria of NIFTP. The incidence of NIFTP in our cohort was 2.1% of papillary thyroid cancer cases during the studied time period. Mean follow-up was 5.7 years (range 0-11). Five patients were identified with nodal metastasis and one patient with distant metastasis. Overall, six patients showed evidence of malignant behavior representing 6% of patients with NIFTP. CONCLUSION: Our study demonstrates that the incidence of NIFTP is significantly lower than previously thought. Furthermore, evidence of malignant behavior was seen in a significant number of NIFTPpatients. Although the authors fully support the de-escalation of aggressive treatment for low-risk thyroid cancers, NIFTP behaves as a low-risk thyroid cancer rather than a benign entity and ongoing surveillance is warranted.
Authors: Tarik M Elsheikh; Sylvia L Asa; John K C Chan; Ronald A DeLellis; Clara S Heffess; Virginia A LiVolsi; Bruce M Wenig Journal: Am J Clin Pathol Date: 2008-11 Impact factor: 2.493
Authors: Yuri E Nikiforov; Raja R Seethala; Giovanni Tallini; Zubair W Baloch; Fulvio Basolo; Lester D R Thompson; Justine A Barletta; Bruce M Wenig; Abir Al Ghuzlan; Kennichi Kakudo; Thomas J Giordano; Venancio A Alves; Elham Khanafshar; Sylvia L Asa; Adel K El-Naggar; William E Gooding; Steven P Hodak; Ricardo V Lloyd; Guy Maytal; Ozgur Mete; Marina N Nikiforova; Vania Nosé; Mauro Papotti; David N Poller; Peter M Sadow; Arthur S Tischler; R Michael Tuttle; Kathryn B Wall; Virginia A LiVolsi; Gregory W Randolph; Ronald A Ghossein Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777
Authors: Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae Journal: Am J Surg Pathol Date: 2004-10 Impact factor: 6.394
Authors: Chan Kwon Jung; Mark P Little; Jay H Lubin; Alina V Brenner; Samuel A Wells; Alice J Sigurdson; Yuri E Nikiforov Journal: J Clin Endocrinol Metab Date: 2013-11-18 Impact factor: 5.958
Authors: Miguel Paja; Carles Zafón; Carmela Iglesias; Aitziber Ugalde; Jose Manuel Cameselle-Teijeiro; Gemma Rodríguez-Carnero; Pilar Fernández-Seara; Emma Anda; Antónia Povoa; Hernán Quiceno; Nancy M Sánchez-Gómez; Clarisa González; Luis García-Pascual; Inés Gómez de la Riva; Concha Blanco; Telma Meizoso; Garcilaso Riesco-Eizaguirre; Ismael Capel; María Victoria Ortega; Isabel Mancha; Montserrat Chao; Victoria Alcázar; Esther Roselló; Javier Maravall; Susana López-Agulló; Antonia Pérez-Lázaro; Pascual Meseguer; Javier Sanz; Jose J Paricio; Saioa Echeverría; Ángel Castaño; Rosa M Bella Journal: Endocrine Date: 2021-01-23 Impact factor: 3.633
Authors: Yuri E Nikiforov; Zubair W Baloch; Steven P Hodak; Thomas J Giordano; Ricardo V Lloyd; Raja R Seethala; Bruce M Wenig Journal: JAMA Oncol Date: 2018-08-01 Impact factor: 31.777
Authors: David N Parente; Pim J Bongers; Raoul Verzijl; Lorne E Rotstein; Sylvia L Asa; Wouter P Kluijfhout; Karen M Devon; David P Goldstein; Ozgur Mete; Jesse D Pasternak Journal: World J Surg Date: 2018-07 Impact factor: 3.352
Authors: Bin Xu; Rene Serrette; R Michael Tuttle; Bayan Alzumaili; Ian Ganly; Nora Katabi; Giovanni Tallini; Ronald Ghossein Journal: Thyroid Date: 2019-10-10 Impact factor: 6.568